Streamline Your Nanobody Development with the Therapeutic Nanobody Profiler on Vecura

What is the Therapeutic Nanobody Profiler?

The Therapeutic Nanobody Profiler (TNP) is an open-source computational tool specifically designed to assess the developability of nanobody (VHH single-domain antibody) sequences. By calculating six critical biophysical metrics, it provides a "traffic-light" (green/amber/red) flagging system to identify potential risks like aggregation or poor solubility. It bridges the gap between sequence design and experimental testing by leveraging structural modeling to predict stability issues before they occur in the lab.

It helps users triage nanobody candidates, eliminate high-risk sequences early in the pipeline, and focus experimental resources on candidates that align with clinical-stage benchmarks. It is especially useful for researchers working with immune libraries, computational design, or directed evolution.

What can users do with the Therapeutic Nanobody Profiler on Vecura?

With the Therapeutic Nanobody Profiler on Vecura, users can:

• Profile Candidates: Quickly assess the developability of individual nanobody sequences.
• Identify Risks: Use the traffic-light flags to instantly spot potential aggregation or viscosity issues.
• Analyze Structural Metrics: Obtain calculated CDR lengths, CDR3 compactness, and surface patch scores (hydrophobicity, positive charge, negative charge).
• Visualize Structures: Generate and export a full-atom 3D model (PDB) of the nanobody for further structural investigation.

What the output means

The output provides a comprehensive report including a set of six quantitative metrics, traffic-light flags for each metric, a signature of the nanobody's "hallmark tetrad," and a 3D structural model in PDB format.

This output should be used to support scientific decision making. It does not replace experimental validation.

Why this matters

In the development of therapeutic nanobodies, identifying stability and developability issues early is crucial for success. Many candidates fail during late-stage development due to aggregation, poor solubility, or unintended non-specific binding. By automating the screening process with metrics calibrated against clinical-stage nanobodies, researchers can significantly reduce the cost and time associated with laboratory testing of suboptimal candidates.

The Therapeutic Nanobody Profiler serves as the VHH-specific counterpart to the established Therapeutic Antibody Profiler (TAP), ensuring that nanobody engineers have specialized, data-driven tools for their unique protein architectures.

• Developed by: Oxford Protein Informatics Group (OPIG)
• Source: Official GitHub Repository
• Reference: Original paper (bioRxiv)